Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer.
acute generalized exanthematous pustulosis
adverse event
apalutamide
skin rash
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
20
06
2022
accepted:
06
08
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Acute generalized exanthematous pustulosis is a type of severe cutaneous drug adverse reaction. While apalutamide is known for its high incidence of cutaneous adverse events, it remains unknown whether acute generalized exanthematous pustulosis can develop during apalutamide treatment. A 72-year-old man with metastatic castration-sensitive prostate cancer developed small erythema on the face and trunk after 41 days of apalutamide treatment. Three days later, apalutamide was discontinued. However, 9 days after the discontinuation of apalutamide, the patient had a high fever with hemodynamic instability and showed diffuse erythema throughout the body with numerous small pustules. Skin biopsy revealed subcorneal and intraepidermal pustules admixed with many eosinophils, which led to the diagnosis of acute generalized exanthematous pustulosis. The skin rash improved in 14 days with systemic corticosteroid administration. We present the first case of a skin rash with clinical features of acute generalized exanthematous pustulosis during apalutamide treatment.
Identifiants
pubmed: 36341202
doi: 10.1002/iju5.12525
pii: IJU512525
pmc: PMC9626358
doi:
Types de publication
Case Reports
Langues
eng
Pagination
497-500Informations de copyright
© 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.
Déclaration de conflit d'intérêts
MS has received lecture fees from Janssen Pharmaceutical K.K.
Références
JAMA Dermatol. 2022 Feb 1;158(2):176-183
pubmed: 34985493
Int J Clin Oncol. 2019 Dec;24(12):1596-1604
pubmed: 31446511
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
J Dermatol. 2012 Dec;39(12):1077-8
pubmed: 22901319
BMC Urol. 2020 Sep 2;20(1):139
pubmed: 32878613
Orphanet J Rare Dis. 2012 Sep 25;7:72
pubmed: 23009177
J Dermatol. 2020 Oct;47(10):e359-e360
pubmed: 32662533
J Cutan Pathol. 2001 Mar;28(3):113-9
pubmed: 11168761
Int J Dermatol. 2021 Aug;60(8):e315-e317
pubmed: 33559145
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Br J Dermatol. 2013 Nov;169(5):1071-80
pubmed: 23855313
Int J Clin Oncol. 2022 Aug;27(8):1348-1355
pubmed: 35596089
Br J Dermatol. 2007 Mar;156(3):609-11
pubmed: 17300272
IJU Case Rep. 2021 Jun 27;4(5):299-302
pubmed: 34497989